Dr. Raymond J. Hohl, MD

Dr. Hohl practices at Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State.

Dr. Hohl's NPI, 1710975651, was assigned on October 13, 2005. Dr. Hohl graduated from Rush Medical College of Rush University in 1984. Dr. Hohl holds Pennsylvania license MD451620.

Dr. Hohl's primary practice is Penn State Health Milton S. Hershey Medical Center, at 500 University Drive, Hershey, PA 17033 in Dauphin County. The practice phone is (717) 531-8521.

Dr. Hohl's primary practice is Penn State Health Milton S. Hershey Medical Center in Hershey, Pennsylvania, part of Penn State. Dr. Hohl is also affiliated with Penn State Health Lancaster Medical Center. The medical group on file is Penn State Health Milton S. Hershey Medical Center. Dmand AI also links Dr. Hohl to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hohl practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hohl's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Hohl's licenses on file in 2 states: Pennsylvania and Iowa.

CMS data shows 463 Medicare services from Dr. Hohl across 2 procedure codes in 2024, all of them office visits, for 103 Medicare patients. Medicare paid $33,702 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 103 Medicare patients who saw Dr. Hohl in 2024. The largest group is 65 to 74, with 54 patients. 68% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hohl's median patient age at 73, with 43% women.

In 2024, Dr. Hohl wrote 760 Medicare Part D claims for 83 patients. 77% of them were for generic drugs. CMS names the drug for 439 of them, across 27 drugs with 11 or more claims each, at $1,347,324 in total drug cost. In 2023, CMS named 397 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Hohl for performance year 2024, reported as part of a group. Dr. Hohl accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 56 papers to Dr. Hohl, published from 2011 to 2024. 2022 was the busiest year, with 7. The most frequent topics are Antineoplastic Agents, Cell Line, Tumor and Polyisoprenyl Phosphates. Dr. Hohl has published most often in Clin Pharmacol Ther. Dr. Hohl's most frequent co-authors are David F. Claxton, MD, Shin Mineishi, MD and Seema Girish Naik, MD.

CMS Open Payments shows 29 general payments to Dr. Hohl from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Eli Lilly and Company paid the most, $313.

Dr. Hohl graduated from Rush Medical College of Rush University in 1984.